Ehlerding, Götz
Ries, Wolfgang
Kempkes-Koch, Manuela
Ziegler, Ekkehard
Ronová, Petra
Krizsán, Mária
Verešová, Jana
Böke, Mária
Erlenkötter, Ansgar
Nitschel, Robert
Zawada, Adam M.
Kennedy, James P.
Braun, Jennifer
Larkin, John W.
Korolev, Natalia
Lang, Thomas
Ottillinger, Bertram
Stauss-Grabo, Manuela
Griesshaber, Bettina
Article History
Received: 22 April 2024
Accepted: 18 June 2024
First Online: 10 July 2024
Declarations
:
: This study was approved by the Ethics Committees Ärztekammer Niedersachsen/Schleswig-Holstein in Germany (Approval Reference: BO/49/2020), IKEM in Czech Republic (Approval Reference: 26370/20, A-20-27) and OGYEI/TUKEB in Hungary (Approval Reference: OGYÉI/1063/2021). This study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and informed consent was obtained from each patient.
: Not applicable.
: AE, RN, AMZ, JPK, JB, JWL, NK, TL, MSG, and BG are full-time employees of Fresenius Medical Care and report personal fees from Fresenius Medical Care, outside the submitted work. GE, WR, MKK, EZ, PR, MK, JV, and MB report grants, personal fees, and non-financial support from Fresenius Medical Care, during the conduct of the study; JWL reports having share options/ownership in Fresenius Medical Care, being an inventor on patent(s) in the field of dialysis, receipt of honorarium from The Lancet, being on the Editorial Board of Frontiers in Physiology and Frontiers in Medicine, Nephrology, and being a member on the Steering Committee of the MONitoring Dialysis Outcomes (MONDO) initiative. BO reports personal fees from Fresenius Medical Care received during the conduct and after the study. The results presented in this paper have not been published previously in whole or part, except in abstract format at the ERA Nephrology Congress 2023, Milan, Italy.